AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01476358 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin A (retinyl palmitate).
Description: Active Comparator (Vitamin A): 1 capsule containing oil carrier and 50,000IU Vitamin A, within 48hs of birth~Placebo Comparator: 1 capsule containing oil carrier and 0IU Vitamin A, within 48hs of birth
Study NCT04550442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given IV or SC
Study NCT04550442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study NCT01729364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: crystalloid
Study NCT01729364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: colloid
Study NCT02110121 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Picosure Laser System
Description: Picosure Laser System for the Treatment of Unwanted Tattoos
Study NCT02110121 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Revlite Laser System
Description: Revlite Laser System for the Treatment of Unwanted Tattoos
Study NCT02110134 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Revlite Laser System with hydroquinone skin care regimen
Description: Revlite Laser System with hydroquinone skin care regimen for the Treatment of Melasma
Study NCT02110134 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hydroquinone skin care regimen
Description: Hydroquinone skin care regimen for the Treatment of Melasma
Study NCT01653704 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: observational role
Description: observational role in crisis scenario
Study NCT01653704 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: active role
Description: active role in managing crisis scenario
Study NCT03619980 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: Retrospective study to evaluate time to event and healthcare resource utilisation of prostate cancer patients throughout the different disease stages, until progression or death.
Study NCT02967926 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Retrograde Cholangioscopy by SpyGlass (ERCS)
Description: Digital SpyGlass Cholangioscopy to facilitate common bile duct stone removal
Study NCT02552082 — intervention group
Intervention type: DEVICE
Intervention: Scorpio NRG posterior stabilized (PS)
Study NCT01812603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sativex
Description: Administered orally as a spray to the cheek according to a standard dose titration regimen, until patients reach a maximum tolerated dose (maximum 12 sprays per day). Each spray delivers 100 μl (Δ9tetrahydrocannabinol (THC), 27 mg/ml: Cannabidiol (CBD), 25 mg/ml).
Study NCT03692455 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Roux-en-Y Gastric Bypass
Description: The Roux-en-Y gastric bypass procedure involves creating a stomach pouch out of a small portion of the stomach and attaching it directly to the small intestine, bypassing a large part of the stomach and duodenum. Not only is the stomach pouch too small to hold large amounts of food, but by skipping the duodenum, fat absorption is substantially reduced.
Study NCT03692455 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vertical Sleeve Gastrectomy
Description: VSG surgery restricts food intake and decreases the amount of food used. Most of the stomach is removed during this surgery, which may decrease ghrelin, a hormone that prompts appetite. Lower amounts of ghrelin may reduce hunger more than other purely restrictive surgeries, such as AGB.
Study NCT02207582 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Verum Prefrontal tRNS
Description: 2mA of tRNS (DC-Stimulator, NeuroConn GmbH, Germany) with a zero offset will be applied to the left and right dorsolateral prefrontal cortex. Treatment will consist of 15 days with 20 minutes stimulation per day. Voltage will be ramped at the begin and end of a stimulation for 10 seconds.
Study NCT02207582 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Prefrontal tRNS
Description: 2mA of tRNS (DC-Stimulator, NeuroConn GmbH, Germany) with a zero offset will be applied to the left and right dorsolateral prefrontal cortex. Treatment will consist of 15 days with 20 minutes stimulation per day. Voltage will be ramped at the begin and end of a stimulation for 10 seconds. Placebo stimulation will consist of just applying the ramps at the begin and end of the stimulation.
Study NCT03610217 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary arterial hypertension algorithm
Description: Patients diagnosed with pulmonary arterial hypertension secondary to systemic sclerosis will be randomized to receive anticoagulation (warfarin, rivaroxaban or apixaban)
Study NCT00004856 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: Given IV
Study NCT04052126 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualized physical activity program
Description: Participants who agreed to participate in the study will participate in an individualized 6-month physical activity (PA) program, consisting of 3 periods: initiation (1st month), transition (2nd-3rd months) and autonomy (4th-6th months). It is based on 4 PA modalities:~The supervised PA session in a sterile room or at home once a week during the initiation and transition phases (20-45 min, low-to-moderate intensity, walking, muscle strengthening, balance and flexibility exercises).~The unsupervised PA session in a sterile room or at home once a week during the transition phase and twice a week during the autonomy phase (same as supervised session).~Follow-up by telephone once a month during the autonomy phase (30 min, support to PA).~Continuously wearing an activity tracker throughout the entire program (promotion of walking).~Activities are planned over a period of 6 months to achieve an intervention that meets the key principles of progression, specificity and empowerment.
Study NCT03610217 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Raynaud's phenomenon algorithm
Description: Patients with mild Raynaud's phenomenon not responding to the first line treatment (nifedipine), will be randomized to receive losartan or nifedipine plus atorvastatin or nifedipine plus losartan. If they fail the second line they will be crossed over to the other options randomly.~Patients with severe Raynaud's phenomenon not responding to the first line treatment (nifedipine) or failing the previous mild Raynaud's algorithm, will be randomized to receive nifedipine plus sildenafil or nifedipine plus intravenous iloprost. If they fail the second line they will be crossed over to the other option.
Study NCT03610217 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital ulcer algorithm
Description: Patients with active digital ulcers not healing after 3 months or developing new ones with nifedipine will be randomized to nifedipine plus sildenafil or nifedipine plus intravenous iloprost. If they fail the second line they will be crossed over to the other option.~Patients who develop new digital ulcers under treatment with nifedipine will be randomized to nifedipine plus atorvastatin plus standard of care or nifedipine plus standard of care. If they fail the second line they will be crossed over to the other option.
Study NCT03610217 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inflammatory arthritis algorithm
Description: Patients with inflammatory arthritis failing methotrexate and/or prednisone and/or hydroxychloroquine and/or sulfasalazine will be randomized to receive intravenous rituximab or subcutaneous tocilizumab. If they fail the second line they will be crossed over to the other option.
Study NCT03610217 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gastroesophageal reflux algorithm
Description: Patients with gastroesophageal reflux failing standard doses of proton pump inhibitors (PPI) will be randomized to receive double doses of PPI or standard dose of PPI plus ranitidine or double doses of PPI plus domperidone or double doses of PPI plus prucalopride/erythromycin. If they fail the second line they will be crossed over to the other options randomly.
Study NCT03610217 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bacterial overgrowth algorithm
Description: Patients with bacterial overgrowth will be randomized to receive erythromycin or metronidazole or amoxicillin. If they fail the second line they will be crossed over to the other options randomly.
Study NCT04218487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xuefu-Zhuyu Capsule
Description: treatment with 2.4g (6 capsules) of XFZY three times daily for 12 weeks.
Study NCT04218487 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: treatment with 2.4g (6 capsules) of placebo three times daily for 12 weeks.
Study NCT04218487 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: conventional therapy
Description: conventional therapy will be given according to the suffering diseases including stable coronary heart disease, chronic insomnia, headache, endometriosis.
Study NCT04218487 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional therapy
Description: conventional therapy will be given according to the suffering diseases including stable coronary heart disease, chronic insomnia, headache, endometriosis.
Study NCT02350257 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based CBT
Description: 12 weeks of internet-based CBT
Study NCT03250117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropinirole oral product
Description: oral immediate-release ropinirole
Study NCT03250117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropinirole Implant
Description: ropinirole hydrochloride/ethylene vinyl acetate
Study NCT04015024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKLB1028 150mg bid
Description: 150mg oral administration twice a day
Study NCT04015024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKLB1028 200mg bid
Description: 200mg oral administration twice a day
Study NCT04015024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKLB1028 300mg qd
Description: 300mg oral administration once a day
Study NCT00238615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 20 mg/m2, 75 mg/m2 infusion
Study NCT00238615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC of 2 and 6 infusion
Study NCT00238615 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: NEOADJUVANT RADIOTHERAPY Radiation therapy will be concurrent with the chemotherapy. Radiation therapy will begin within 24 hours of chemotherapy. CONSOLIDATION RADIOTHERAPY Patients with positive surgical margins or incomplete resection (tumor shaved from spine or great vessels) will receive an additional boost of radiotherapy 3 to 6 weeks after surgery. This will be a 16 Gy boost given with concurrent weekly chemotherapy as during the neoadjuvant period.
Study NCT00238615 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical resection
Description: All patients will be taken to surgical excision, unless they have developed a condition other than progressive disease, which would make surgery unsafe.
Study NCT02037854 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrient formulation
Study NCT02037854 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Nutrient formulation
Study NCT01824576 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ITPR
Description: Single use noninvasive device that is connected to a vacuum source and a means to deliver a positive pressure breath. The device generates negative pressure during the expiratory phase, thus creating subatmospheric intrathoracic pressure between the periods of positive pressure ventilations.
Study NCT01993940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naldemedine
Description: Naldemedine 0.2 mg tablet taken orally once a day
Study NCT01993940 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet taken orally once a day
Study NCT00363363 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: Children in this arm of the study will be provided with specific activities to be completed on most days of the week. The selected activities will be based on the child's interests and results of the baseline measures of health-related PA, MVPA and gross motor skill. The resources and facilities available to the family and season of the year will also influence the choice of activities. The frequency and duration of the required activities will be gradually increased until the child's baseline MVPA has been increased by a minimum of 30 minutes per day, most days of the week. Once that increase is achieved, the activities will be modified to maintain and reinforce the higher PA level.
Study NCT00363363 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Children in this arm of the study will be provided with puzzles, stories and games to be completed each week. The selected activities will be based on the child's interests and designed to increase the child's knowledge of activity options, perceptions of activity benefits, self-confidence for activity participation and motivation for daily activity. The activities introduced will vary with the resources available to the family and the season of the year, and will include information about healthy eating, injury prevention, and healthy lifestyle options.
Study NCT03647917 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma
Description: Autologous Platelet Rich Plasma (PRP) will be isolated from the blood collected from each subject at each treatment time point.~Face: Using a 30 gage needle, about four points of PRP or saline will be injected into the malar area; about six points will be injected into the mandibular area; and seven points will be injected into the forehead (0.2 mL per point) with a total volume of approximately 3.5 mL. PRP and saline application will be followed by microneedling.~Hands: Using a 30 gage needle about 1 cc of PRP or saline will be injected into the dorsal area of the hands (0.2mL per point) at five points. No microneedling will be performed on the hands.
Study NCT03634735 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thiamine
Description: Vitamine B1
Study NCT03634735 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets
Study NCT00867919 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Family Treatment
Description: 11 to 15 sessions of a cognitive behavioral family therapy that will be developed during the course of this study and will address the following:~* parent-adolescent conflict~* adolescent development~* support and closeness~* behavioral activation~* response to adolescent negative affect~* relapse prevention~* suicide prevention, if necessary
Study NCT04467853 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LCAR-C18S cells
Description: Before treatment with LCAR-C18S cells, subjects will receive a conditioning regimen
Study NCT00867919 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Community-based treatment as usual
Description: Treatment as usual, which will most likely consist of 8 to 10 sessions of community-based depression treatment
Study NCT03610217 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Constipation algorithm
Description: Patients with constipation will be randomized to receive bisacodyl or magnesium sulphate or polyethylene glycol or senna.If they fail the second line they will be crossed over to the other options randomly.
Study NCT03610217 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skin involvement algorithm
Description: Patients with skin involvement and modified Rodnan skin score \<32 will be randomized to receive methotrexate or mycophenolic acid or methotrexate plus mycophenolic acid. If they fail the second line they will be crossed over to the other option.~Patients with skin involvement and modified Rodnan skin score >32 will be randomized to receive methotrexate plus mycophenolic acid or intravenous cyclophosphamide. If they fail the second line they will be crossed over to the other option.
Study NCT03610217 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain algorithm
Description: Patients with pain failing first line treatment with acetaminophen or celecoxib or ibuprofen will be randomized to receive pregabalin or duloxetine. Patients with skin involvement and modified Rodnan skin score \<32 will be randomized to receive methotrexate or mycophenolic acid or methotrexate plus mycophenolic acid. If they fail the second line they will be crossed over to the other option. In case they fail the second line they will be treated with medical marijuana.
Study NCT00940134 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PYY 3-36
Description: 0.8 pmol/kg/min x 3 hours
Study NCT00940134 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PYY 3-36
Description: 0.8 pmol/kg/min x 3 hours
Study NCT00940134 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GLP-1
Description: 1.0 pmol/kg/min x 3 hours
Study NCT00940134 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GLP-1
Description: 1.0 pmol/kg/min x 3 hours
Study NCT01207856 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: specific cognitive rehabilitation
Description: Individual rehabilitation procedures will be focused on attention, executive functions, IPS and working memory. The program will be tailored to each patient cognitive status depending on the impairments identified during the initial assessment while maintaining a systematic work on attention and executive functions. A total of 50 sessions lasting one hour at a rate of 3 sessions per week for a total period of 4 months will be proposed. Sessions will include varied exercises according to complexity and presentation modality, using computerized and paper-and-pencil tasks and metacognitive training. Work will be progressive, depending on the progresses achieved (increase complexity and intensity of the exercises according to success at the previous level of exercises).
Study NCT01207856 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: non specific cognitive rehabilitation
Description: A total of 50 sessions lasting one hour at a rate of 3 sessions per week for a total period of 4 months will be proposed by group composed to 5 patients
Study NCT02805218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-rhG-CSF
Study NCT06077630 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: There is no intervention, observational study
Study NCT04146584 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sofwave Treatments
Description: The device used in this study will be the SofWave system manufactured by SofWave Medical ltd. The SofWave device is an ultrasonic system combined with an inherent cooling system that generates High Intensity non-focused Ultrasonic pulses (HIUS), causing a controlled thermal damage by elevating the temperature to 60-70°C in the dermis layer while sparing the epidermal layer using surface cooling. Each patient would receive 2 Sofwave treatments on the face and/or the neck.
Study NCT03499041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3314814
Description: Administered orally
Study NCT00940134 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: saline infusion
Description: saline infusion x 3 hours
Study NCT00480454 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MVA 85A
Description: intradermal vaccine
Study NCT01518192 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxycycline
Description: 100 mg bid; 15 days
Study NCT01518192 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cefuroxime axetil
Description: 500 mg bid; 15 days
Study NCT03412422 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: fluid responsiveness assessment
Description: During the procedure, the investigator will be imaging one of the carotid arteries with ultrasound. In expiratory phase, four sets of three video loops will be recorded: before and after PLR and then before and after fluid challenge. There also will be noted hemodynamic parameters measured with PiCCO monitor. The fluid challenge is defined as administration of 500ml of crystalloid in less than 10 minutes. Later, another investigator, who will be blinded to other data, will measure the maximal and minimal diameter of CCA in each loop. The measurements will be averaged and eventually two values (maximal an minimal) from each set will be obtained.
Study NCT00392444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate
Description: Given orally
Study NCT04579055 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1-min STS test: adjusted
Description: Individually adjusted chair seat height of 90° knee joint flexion
Study NCT04579055 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 1-min STS test: standardized
Description: Standardized chair seat height of 46 cm
Study NCT02041351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: evaluate the activity of docetaxel on, metastatic lesions when measured after 4 cycles of chemotherapy
Study NCT02096926 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02096926 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: 400 mg PO
Study NCT01207856 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: no intervention
Description: no intervention